Because increased EGFR activity contributes to the progression of NASH to HCC in preclinical models, these results indicate that inducing RECK has the potential to inhibit hepatocellular inflammation in the setting of NASH and HCC [38]. This evidence concerns the gene EGFR and hepatocellular carcinoma.